Hepatitis D Virus Antigen ELISA Kit (DEIA073)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma
Species Reactivity
Intended Use
This kit is an enzyme-linked immunosorbent assay (ELISA) for qualitative determination of antigens to hepatitis D virus (HDV- Ag) in human serum or plasma (EDTA, heparin and Sodium Citrate). It is intended for use in clinical laboratories for diagnosis of patients related to infection with hepatitis D virus, and is good for the survey of epidemics.
Contents of Kit
Microplate: 96 well polystyrene microplates (12 strips of 8 wells) coated with purified antibodies reactive to HDV;
Negative Control: 1 ml, 1 vial;
Positive Control: 1 ml, 1 vial;
HRP-Conjugate Antigen: 6ml, 1 vial;
Extraction Solution: 6 ml, 1 vial;
TMB Solution A: 6 ml, 1 vial;
TMB Solution B: 6 ml, 1 vial;
TMB Stop Solution: 6 ml, 1 vial;
Wash Buffer (20×): 50 ml, 1 vial;
Microtiter plate sealers: 3 sheets;
Plastic Sealable Bag: 1 unit.
Store the kit reagents at 2-8°C. For more detailed information, please download the following document on our website.


Have you cited DEIA073 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses?


Authors: Spaan, M.; Carey, I.; Bruce, M.; Shang, D.; Dusheiko, G.; Agarwal, K.

Viral Hepatitis Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention


Authors: Lanini, Simone; Ustianowski, Andrew; Pisapia, Raffaella; Zumla, Alimuddin; Ippolito, Giuseppe

Viral hepatitis is a major global public health problem affecting hundreds of millions of people and is associated with significant morbidity and mortality. Five major biologically unrelated hepatotropic viruses cause most of the global burden of viral hepatitis. Hepatitis B and hepatitis C are associated with a significant number of chronic infections. Most deaths from viral hepatitis are due to hepatitis B and hepatitis C. An estimated 257 million people were living with HBV and 71 million people were living with HCV. Most people are asymptomatic. New diagnostics and highly effective, pangenotypic direct-acting antivirals provide opportunities to cure and eradicate chronic hepatitis C virus infection.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket